Studies using the CDK4/6 inhibitor Palbociclib and the HIF-2α inhibitor PT2399 have demonstrated synergy in suppressing the viability of HIF-2α–dependent ccRCC cell lines [50]. This evidence concerns the gene EPAS1 and nonpapillary renal cell carcinoma.